Search Instructions:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (1475 total)
-
Creator: The REMAP-CAP Investigators
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-25
Description: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. -
Creator: DiLorenzo, M. A., C. A. Baker, J. J. Herstein, L. Evans, J. J. Lowe, S. G. Gibbs, and N. Bhadelia.
Subject: Emergency Management
Item Type: Publication
Date Last Updated: 2021-02-15
Description: In response to the 2013-2016 Ebola virus disease outbreak, the US government designated certain healthcare institutions as Ebola treatment centers (ETCs) to better prepare for future emerging infectious disease outbreaks. This study investigated ETC… -
Creator: Dugdale, C. M., D. M. Rubins, H. Lee, S. M. McCluskey, E. T. Ryan, C. N. Kotton, R. M. Hurtado, A. L. Ciaranello, M. B. Barshak, D. S. McEvoy, S. B. Nelson, N. Basgoz, J. E. Lazarus, L. C. Ivers, J. L. Reedy, K. M. Hysell, J. E. Lemieux, H. M.…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-10
Description: Isolation of hospitalized persons under investigation (PUIs) for COVID-19 reduces nosocomial transmission risk. Efficient PUI evaluation is needed to preserve scarce healthcare resources. We describe the development, implementation, and outcomes of… -
Creator: the Ambulatory COVID Study Team
Subject: Research
Item Type: Publication
Date Last Updated: 2021-01-05
Description: Outpatient coronavirus disease 2019 (COVID-19) has been insufficiently characterized. To determine the progression of disease and determinants of hospitalization, we conducted a prospective cohort study. -
Creator: the PlasmAr Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-18
Description: Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled… -
Creator: the Fundación INFANT–COVID-19 Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-18
Description: Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier… -
Creator: Wu, Kai, Anne P. Werner, Matthew Koch, Angela Choi, Elisabeth Narayanan, Guillaume B. E. Stewart-Jones, Tonya Colpitts, Hamilton Bennett, Seyhan Boyoglu-Barnum, Wei Shi, Juan I. Moliva, Nancy J. Sullivan, Barney S. Graham, Andrea Carfi, Kizzmekia S.…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-17
Description: The mRNA-1273 vaccine against SARS-CoV-2 elicited high neutralizing-antibody titers in phase 1 trial participants and has been shown to be highly efficacious in preventing symptomatic Covid-19 disease and severe disease. -
Creator: Liu, Yang, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila R. Fontes-Garfias, Kena A. Swanson, Hui Cai, Ritu Sarkar, Wei Chen, Mark Cutler, David Cooper, Scott C. Weaver, Alexander Muik, Ugur Sahin, Kathrin U. Jansen, Xuping Xie, Philip R.…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-17
Description: BNT162b2 is a nucleoside-modified RNA vaccine expressing the full-length prefusion spike glycoprotein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In a randomized, placebo-controlled clinical trial involving approximately… -
Creator: the Oxford COVID Vaccine Trial Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-19
Description: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. -
Creator: the Oxford University Hospitals Staff Testing Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-11
Description: The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear.Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.